Oral diseases · 2026
SOX2 As a Biomarker of Pathological Response in Oral Cavity Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sharma Aishwarya, Kaur Najinder Preet, Mohamedali Rasheeda, Gupta Heena, Gupta Nitika, Sau Aratrika, Dey Pranab, Somal Puneet, Nishith Nilay, Pawar Ravikiransingh, Sancheti Sankalp, Ganju Prabhat, Sood Sahil, Thakur Pragyat, Mittal Sahil, Kansal Latika
Аннотация
BACKGROUND: Neoadjuvant chemotherapy response is highly variable in locally advanced oral cavity squamous cell carcinoma. SOX2, a stemness-associated transcription factor, promotes chemoresistance through cancer stem cell maintenance. No prior study has evaluated pretreatment SOX2 protein expression as a predictor of pathological response to neoadjuvant chemotherapy in this disease. We present the first retrospective evaluation of this question, assessed against the Hirakawa tumour regression grading system.
METHODS: Fifty-four patients with locally advanced oral cavity squamous cell carcinoma receiving neoadjuvant chemotherapy followed by curative surgery were analysed retrospectively. SOX2 immunohistochemistry was performed on paired pre- and post-treatment specimens in 47 patients, defined as the primary analytic cohort. Pathological response was graded using the Hirakawa tumour regression grading system. Kaplan-Meier and Cox proportional hazards analyses were performed for event-free and overall survival. Subgroup analyses stratified by NACT regimen were additionally performed.
RESULTS: SOX2 negativity was significantly associated with a favourable pathological response (odds ratio 6.22, 95% confidence interval 1.32-29.29, p = 0.021), with a negative predictive value of 82.4%. This association was directionally consistent across NACT subgroups, which did not differ significantly in pathological response or survival. Good responders demonstrated significantly superior event-free survival (p = 0.006). Nodal metastasis was the dominant independent predictor of event-free survival on multivariate Cox analysis (hazard ratio 6.23, p = 0.026).
CONCLUSIONS: SOX2 negativity at baseline is associated with a favourable neoadjuvant chemotherapy response in locally advanced oral cavity squamous cell carcinoma. The Hirakawa tumour regression grading system demonstrated strong prognostic discrimination for event-free survival. Prospective, externally validated evaluation of SOX2 within a multi-marker prediction panel is warranted; these findings should be regarded as hypothesis-generating pending such validation.
METHODS: Fifty-four patients with locally advanced oral cavity squamous cell carcinoma receiving neoadjuvant chemotherapy followed by curative surgery were analysed retrospectively. SOX2 immunohistochemistry was performed on paired pre- and post-treatment specimens in 47 patients, defined as the primary analytic cohort. Pathological response was graded using the Hirakawa tumour regression grading system. Kaplan-Meier and Cox proportional hazards analyses were performed for event-free and overall survival. Subgroup analyses stratified by NACT regimen were additionally performed.
RESULTS: SOX2 negativity was significantly associated with a favourable pathological response (odds ratio 6.22, 95% confidence interval 1.32-29.29, p = 0.021), with a negative predictive value of 82.4%. This association was directionally consistent across NACT subgroups, which did not differ significantly in pathological response or survival. Good responders demonstrated significantly superior event-free survival (p = 0.006). Nodal metastasis was the dominant independent predictor of event-free survival on multivariate Cox analysis (hazard ratio 6.23, p = 0.026).
CONCLUSIONS: SOX2 negativity at baseline is associated with a favourable neoadjuvant chemotherapy response in locally advanced oral cavity squamous cell carcinoma. The Hirakawa tumour regression grading system demonstrated strong prognostic discrimination for event-free survival. Prospective, externally validated evaluation of SOX2 within a multi-marker prediction panel is warranted; these findings should be regarded as hypothesis-generating pending such validation.